A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia

INTRODUCTION: Rituximab plus fludarabine and cyclophosphamide (RFC) is the standard of care for fit patients with untreated chronic lymphocytic leukemia (CLL); however, its use is limited in ‘unfit’ (co-morbid and/or full-dose F-ineligible) patients due to its toxicity profile. We conducted a system...

Descripción completa

Detalles Bibliográficos
Autores principales: Städler, Nicolas, Shang, Aijing, Bosch, Francesc, Briggs, Andrew, Goede, Valentin, Berthier, Aurelien, Renaudin, Corinne, Leblond, Veronique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055565/
https://www.ncbi.nlm.nih.gov/pubmed/27535291
http://dx.doi.org/10.1007/s12325-016-0398-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055565/
https://www.ncbi.nlm.nih.gov/pubmed/27535291
http://dx.doi.org/10.1007/s12325-016-0398-2

Ejemplares similares